硝苯地平缓释微丸家犬体内药动学和生物利用度  

Pharmacokinetics and relative bioavailability of nifedipine sustained release pellets

作　　者：马萍[1] 祝力[2] 孙淑英[2] 辛艳茹[1] 杨京燕[1] 高文静[1] 

机构地区：[1]第二炮兵总医院药剂科,北京100088 [2]沈阳药科大学药剂学教研室,辽宁沈阳100015

出　　处：《广东药学院学报》2004年第1期32-34,共3页Academic Journal of Guangdong College of Pharmacy

摘　　要：目的 :研究硝苯地平缓释微丸在家犬体内的药动学及生物利用度。方法 :家犬自身交叉对照分别口服单剂量硝苯地平缓释微丸 (A)和进口硝苯地平控释片 (B)各 30mg ,采用反相高效液相色谱法测定血药浓度 ,应用 3P87药动学程序对血药浓度数据进行拟合。结果 :硝苯地平缓释微丸和进口硝苯地平控释片的药动学参数 :Tmax分别为 3.4 7和 5 .4 1h ;Cmax分别为2 5 .7和 2 0 .2ng·mL-1 ;AUC0～∞ 分别为 2 1 6和 1 6 8mg·h·mL-1 。以B为参比制剂 ,单剂量给药时A的相对生物利用度为1 2 9%。结论 :两种制剂单剂量给药Objective:To study the pharmacokinetics and relative bioavailability of nifedipine sustained release pellets. Methods: The plasma concentration of nifedipine was determined by HPLC. The data was processed with the software 3P87. Results: The parameters of the two formulations for nifedipine: T max of the pellets and tablets were 3.47 and 5.41 h;C max were 25.7 and 20.2 ng/mL;and AUC 0～∞ were 216 and 168 mg·h·mL -1 respectively. The bioavailability of nifidipine sustained pellets with reference to nifedipine controlled-release tablets is 129%. Conclusions: The results of single oral administration 30 mg nifidipine demonstrated that two formulations were not bioequivalent.

关 键 词：硝苯地平 海藻酸钠 缓释微丸 控释片 药动学 生物利用度 

分 类 号：R96[医药卫生—药理学]